Design Therapeutics, Inc. (DSGN) Income Statement
DSGN 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsDSGN revenue and net income
DSGN profit margins
DSGN growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
DSGN quarterly EPS vs estimates
Design Therapeutics beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: November 4, 2026 (estimate $-0.38).
DSGN income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $226 | $834,000 |
| Cost of revenue | $622,000 | $596,000 | $537,000 | $466,000 | $129,000 | $5,000 | $1,654 |
| Gross profit | −$622,000 | −$596,000 | −$537,000 | −$466,000 | −$129,000 | −$5,000 | −$820 |
| Research & development | $59.1M | $44.4M | $57.1M | $48.6M | $24.8M | $6.1M | $1.7M |
| Sales, general & admin | $20.3M | $18.0M | $21.1M | $19.0M | $11.1M | $2.5M | $1.1M |
| Total operating expenses | $79.5M | $62.4M | $77.7M | $67.6M | $35.8M | $8.6M | $1.9M |
| Operating income | −$79.5M | −$62.4M | −$78.2M | −$67.6M | −$35.8M | −$8.6M | −$1.9M |
| Interest income | $9.7M | $12.8M | $11.3M | — | — | — | — |
| Interest expense | — | — | — | $4.7M | $298,000 | $0 | $0 |
| Income before taxes | −$69.8M | −$49.6M | −$66.9M | −$63.3M | −$35.5M | −$8.3M | −$2.0M |
| Income taxes | — | — | −$1 | −$4.7M | −$107,558 | −$201,297 | $139,000 |
| Net income | −$69.8M | −$49.6M | −$66.9M | −$58.6M | −$35.5M | −$8.3M | −$2.0M |
| EBITDA | −$69.2M | −$49.0M | −$66.3M | −$67.2M | −$35.4M | −$8.3M | −$1.9M |
| EPS (diluted) | −$1.22 | −$0.88 | −$1.20 | −$1.14 | −$0.86 | −$0.30 | — |
| Gross margin | — | — | — | — | — | −2,212.4% | −0.1% |
| Operating margin | — | — | — | — | — | −3,785,840.7% | −228.8% |
| Net margin | — | — | — | — | — | −3,663,716.8% | −245.4% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $588,000 | $0 | $0 | $0 | $838,000 | $0 |
| Cost of revenue | $151,000 | — | −$14.7M | $14.6M | $152,000 | $159,000 | $149,000 | $153,000 | $151,000 | $143,000 | $138,000 | $137,000 |
| Gross profit | −$151,000 | — | $14.7M | −$14.6M | −$152,000 | −$159,000 | $294,000 | −$153,000 | −$151,000 | −$143,000 | −$138,000 | −$137,000 |
| Research & development | $16.4M | $14.4M | $13.4M | $14.6M | $15.7M | $15.4M | $12.2M | $11.9M | $10.4M | $9.7M | $11.0M | $13.3M |
| Sales, general & admin | $5.8M | $5.3M | $4.8M | $4.8M | $5.8M | $5.0M | $4.5M | $4.4M | $4.5M | $4.6M | $4.1M | $5.6M |
| Total operating expenses | $22.2M | $19.7M | $18.2M | $19.3M | $21.4M | $20.4M | $16.7M | $16.2M | $14.9M | $14.3M | $15.1M | $18.7M |
| Operating income | −$22.2M | −$19.7M | −$18.2M | −$19.3M | −$21.6M | −$20.4M | −$16.7M | −$16.2M | −$15.0M | −$14.4M | −$15.1M | −$18.8M |
| Interest income | $2.0M | $2.1M | $2.2M | $2.3M | $2.5M | $2.7M | — | — | $3.2M | — | — | — |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $129,000 | — |
| Income before taxes | −$20.2M | −$17.6M | −$16.0M | −$17.0M | −$19.1M | −$17.7M | −$13.7M | −$13.0M | −$11.8M | −$11.1M | −$11.8M | −$15.8M |
| Income taxes | — | — | — | — | — | — | — | — | — | $99,724 | $2.5M | −$137,000 |
| Net income | −$20.2M | −$17.6M | −$16.0M | −$17.0M | −$19.1M | −$17.7M | −$13.7M | −$13.0M | −$11.8M | −$11.1M | −$11.8M | −$15.8M |
| EBITDA | −$22.0M | −$17.5M | −$15.8M | −$16.8M | −$18.9M | −$17.6M | −$13.5M | −$12.9M | −$11.6M | −$11.0M | −$11.7M | −$15.7M |
| EPS (diluted) | −$0.32 | −$0.29 | −$0.27 | −$0.30 | −$0.34 | −$0.31 | −$0.24 | −$0.23 | −$0.21 | −$0.20 | −$0.21 | −$0.28 |
| Gross margin | — | — | — | — | — | — | 50.0% | — | — | — | −16.5% | — |
| Operating margin | — | — | — | — | — | — | −2,839.1% | — | — | — | −1,804.4% | — |
| Net margin | — | — | — | — | — | — | −2,321.6% | — | — | — | −1,413.1% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in DSGN's financial statements (latest annual report filed March 9, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
DSGN financial results
Design Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $69.8 million. Diluted earnings per share came to −$1.22.
See the DSGN stock overview for the latest quote and news, or the DSGN chart for price history and technical indicators.
DSGN income statement FAQ
Does Design Therapeutics have revenue?
Design Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Design Therapeutics profitable?
No. Design Therapeutics reported a net loss of $69.8 million in fiscal 2025.
How much does Design Therapeutics spend on research and development?
Design Therapeutics spent $59.1 million on research and development in fiscal 2025.
What are Design Therapeutics's earnings per share?
Design Therapeutics earned $-1.22 per diluted share in fiscal 2025, compared with $-0.88 a year earlier.
When will Design Therapeutics report its next earnings?
Design Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 4, 2026.
When does Design Therapeutics's fiscal year end?
Design Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 9, 2026.